AstraZeneca, Merck secure FDA breakthrough therapy status for selumetinib

Image: AstraZeneca, Merck have secured breakthrough therapy designation for selumetinib to treat pediatric patients with neurofibromatosis type 1. Photo: courtesy of AstraZeneca.